Growing evidence points to a critical pathophysiologic role for angiotensin in the
progression of heart failure and other cardiovascular diseases. This role is probably …

Study Objective. To examine the class effect of angiotensin II receptor blockers (ARBs) on
mortality in patients with heart failure who were aged 65 years or older. Design …

Because of the impressive record of ACE inhibitors in patients with heart failure with reduced
ejection fraction, the renin-angiotensin-aldosterone system continues to be pursued as a …

The paper by Bart et al.[1] published in this issue addresses a clinically important issue. It is
well recognised that despite overwhelming evidence confirming the efficacy of ACE …

Background—The added benefits of angiotensin II type I receptor (AT1) blockers (ARBs) to
ACE inhibition suggests that recommended doses of ACE inhibitors provide only partial …

Angiotensin-converting enzyme (ACE) inhibitors are used in the management of a wide
range of cardiovascular conditions, including congestive heart failure (CHF). Although the …

Heart failure is a common and often debilitating condition, but one for which there exists a
variety of effective pharmacological therapies. The angiotensin converting enzyme (ACE) …

Heart failure remains a major and increasing cause of mortality and morbidity, even when
the best available treatments are used. One of its key causes is neuroendocrine activation …

Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in
the treatment of heart failure; yet only a minority (ie, 30% to 40%) of eligible patients are …

Growing evidence that angiotensin II contributes to the structural abnormalities of the left
ventricle and vasculature that characterize chronic heart failure has made it attractive to …